SCHEMBL20129050

SCHEMBL20129050

Cn1c2ccncc2c2ccc(-c3ccc(O[C@H]4C[C@H](Oc5cccc(OCCCCCCOCc6ccccc6)n5)C4)nc3)cc21

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 4/20 0.39
GBA1 P04062 3/20 0.36
UGCG Q16739 3/20 0.36
GBA2 Q9HCG7 3/20 0.36
HTR1A P08908 1/20 0.34
HTR1D P28221 1/20 0.34
HTR1B P28222 1/20 0.34
CHRNB2 P17787 1/20 0.34
CHRNB4 P30926 1/20 0.34
CHRNA3 P32297 1/20 0.34
CHRNA7 P36544 1/20 0.34
CHRNA4 P43681 1/20 0.34
ATM Q13315 8/20 0.33
MTOR P42345 6/20 0.33
PIK3CA P42336 5/20 0.33
ATR Q13535 5/20 0.33
BACE1 P56817 1/20 0.33
LCT P09848 2/20 0.33
SI P14410 2/20 0.33
MGAM O43451 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20129055 0.90 FAAH (0.37) FAAHGBA1UGCGGBA2CHRNB2
SCHEMBL20129051 0.89 FAAH (0.37) FAAHATMMTORPIK3CAATR
SCHEMBL20128934 0.88 FAAH (0.40) FAAHHTR1AHTR1DHTR1BCHRNB2
SCHEMBL20128974 0.87 ATM (0.40) GBA1UGCGGBA2ATM
SCHEMBL27097783 0.85 NAAA (0.36) FAAHCHRNB2CHRNB4CHRNA3CHRNA7
SCHEMBL20128962 0.85 ATM (0.36) ATMMTORPIK3CAATR
SCHEMBL20129103 0.85 FAAH (0.37) FAAHHTR1AHTR1DHTR1BCHRNB2
SCHEMBL20129048 0.83 FAAH (0.33) FAAHATMMTORPIK3CAATR
SCHEMBL20133191 0.83 FAAH (0.36) FAAHHTR1AHTR1DHTR1BCHRNB2
SCHEMBL20129242 0.82 FAAH (0.37) FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
US-11912699-B2 Tau-protein targeting compounds and associated ARVINAS OPERATIONS, INC. (US) 2024-02-27 US disclosed
WO-2018102067-A2 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE Arvinas, Inc. (US) 2018-06-07 WO disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE ARVINAS OPERATIONS, INC. 2018-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11912699-B2 Tau-protein targeting compounds and associated MAPT, VHL, CRBN FAAH 4345/4885GBA1 3239/4885UGCG 4609/4885
US-20180125821-A1 TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE CRBN, VHL, UBQLN2 FAAH 4290/4885GBA1 3504/4885UGCG 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.